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Why LDL-C Goals Still Matter in Post-ACS Patients*R. Scott Wright, MD,a Joseph Murphy, MDa,bSEE PAGE 353T he sword of Damocles, a term derived fromGreek mythology, refers to the perpetualsense of fear and dread of death under which
speciﬁc individuals, usually leaders, must live.
According to the Greek myth, Damocles, a courtier,
switched places with King Dionysius II, the ruler of
Syracuse (modern day Sicily) who lived circa 350 BC.
Damocles sat on the king’s throne at a great feast
but with the caveat that a large sword should hang
above him, secured only by a precariously thin single
horse hair attached at the sword pommel. Both men
were keenly aware of their own mortality, and it is
implied that both of the men would have gladly
used all means within their power to diminish their
risk of impending death.
Suffering an acute coronary syndrome (ACS) event
in 2015 represents a modern “sword of Damocles”
moment in most patients’ lives; those who survive the
ACS event recognize their own mortality and are
highly motivated to lessen future cardiovascular risks.
Our patients are at a teachable moment in their lives
during hospitalization and the ensuing follow-up pe-
riods; nearly all indicate considerable motivation to
reduce or alleviate future cardiovascular event risks.
Recent data suggest at least a 9% risk of a recurrent
event over the ensuing 3 years following ACS (1), yet
additional risk reduction strategies remain elusive
if we are honest in our assessments. To date, the best
strategy seems to be a coordinated, integrated effort to
apply evidence-based therapies along with life-style*Editorials published in the Journal of the American College of Cardiology
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paper to disclose.modiﬁcation as part of post-ACS cardiac reha-
bilitation education (2,3). Atherosclerosis remains a
challenging disease state to modify, largely secondary
to its diffuse nature within the arterial vascular system
and its underlying inﬂammatory/metabolic etiology
(4). Lipid-altering therapy with statins reduces sub-
sequent cardiovascular events (5). The IMPROVE-IT
(Examining Outcomes in Subjects With Acute Coro-
nary Syndrome: Vytorin [Ezetimibe/Simvastatin] vs
Simvastatin [P04103]) study is the ﬁrst to demon-
strate risk reduction through the combination of
statin and ezetimibe therapies and extends the num-
ber of potential therapies we have to offer our patients
as options to prevent a secondary ACS event (6).The paper by Murphy et al. (7), in this issue of the
Journal, demonstrates a substantial reduction in the
primary endpoint of 9%, withmost of the beneﬁt being
attributed to the ﬁrst of the composite endpoints (56%
of total event reductions); their novel analysis inter-
estingly demonstrates additional beneﬁt to subse-
quent components of the primary endpoint (44%) in
those patients whose ﬁrst event was nonfatal. The
seminal work by Murphy et al. (7) extends previous
work establishing the importance and validity of
evaluating composite endpoint data by dividing the
nonfatal ﬁrst events into initial and subsequent
events. The logic behind these analyses is that
therapies which favorably modify the underlying
pathophysiology should demonstrate a consistent
beneﬁt across all modiﬁable endpoints. Data from
IMPROVE-IT suggest such a beneﬁt. Both initial and
subsequent nonfatal events within the composite
primary endpoint were considerably reduced by
aggressively lowering low-density lipoprotein choles-
terol (LDL-C) with the combination of simvastatin and
ezetimibe compared with simvastatin alone.
Ezetimibe has a unique mechanism of action
different from statin medication by inhibiting the
FIGURE 1 On-Treatment LDL Predicts Clinical Event Rates
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Coronary heart disease (CHD) event rates reported from randomized placebo-controlled
trials using statins for secondary coronary event prevention. Original trial data (red dots)
were used to compute the univariate regression lines correlating low-density lipoprotein
(LDL) with outcomes in the paper by O’Keefe et al. (8) in 2004. The event rate was predicted
to approach zero at an LDL of 30 mg/dl. We added newer studies (blue dots), including the
accompanying IMPROVE-IT paper in this issue of the Journal, that also strongly support the
hypothesis that secondary cardiac events correlate directly with the patient LDL cholesterol
levels. 4S ¼ Scandinavian Simvastatin Survival Study; A2Z ¼ Aggrastat to Zocor; AT ¼
atorvastatin; CARE¼ Cholesterol And Recurrent Events trial; HPS¼ Heart Protection Study;
IMPROVE-IT ¼ The Improved Reduction of Outcomes: Vytorin Efﬁcacy International Trial;
LIPID ¼ Long-term Intervention with Pravastatin In Ischemic Disease trial; P ¼ placebo;
PR¼ pravastatin; PROVE-IT¼ PRavastatin Or atorVastatin Evaluation and Infection Therapy
trial; S¼ statin (10, 20 and 80 refer to statin dose); TNT¼ Treating to New Targets. Modiﬁed
with newer randomized trial results with permission from O’Keefe, Jr., et al. (8).
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363absorption of cholesterol from the small intestine
by blocking a critical mediator of cholesterol absorp-
tion present on gastrointestinal epithelial cells. This
results in a decrease in gut cholesterol availability to
hepatocytes leading to liver LDL absorption from
circulating LDL with a secondary lowering effect on
circulating LDL cholesterol. Thus, the beneﬁcial effect
of ezetimibe on cardiovascular events is likely an
LDL-mediated effect, thus supporting our hypothesis
that LDL-C levels are critical after an ACS event.
The recent publication of the IMPROVE-IT trial
underscored the importance of LDL-C lowering as it
demonstrated an additional 8% relative risk reduc-
tion in patients taking a potent statin with the addi-
tion of ezetimibe that resulted in a modest further
lowering of LDL-C. The observation reinforces the
hypothesis that LDL-C lowering is important and that
lower LDL-C values are associated with reduced car-
diovascular risks as illustrated in Figure 1 (8).
WHY ARE THESE OBSERVATIONS RELEVANT
FOR THE PRACTICING CLINICIAN TREATING
ACS PATIENTS?
The 2013 American College of Cardiology/American
Heart Association (ACC/AHA) cholesterol treatment
guidelines (9) shifted attention and clinical decision
making of the cardiology community away from
absolute patient LDL-C values to a greater emphasis on
the dose or intensity of statin use based on patient
baseline cardiovascular risk proﬁle. Although this
approach may have scientiﬁc merit in hypercholes-
terolemic patients without documented cardiovascu-
lar disease, this approach may not be adequate in
patients with a documented history of a cardiovascular
event. There has been considerable debate, pro and
con, about whether intensity of statin use is most
important or whether a speciﬁc LDL-C goal must be
achieved in post-ACS patients taking lipid-altering
therapy for optimal cardiovascular risk reduction
(10). Higher statin doses equate to more statin adverse
effects and lower patient compliance with statin
medication. The publication of these data directly
challenge the direction the 2013 ACC/AHA guidelines.
These data suggest that LDL-C values on treatment are
more noteworthy in post-ACS patients and that LDL-C
treatment goals should be both measured and acted
upon in post-ACS patients. It is clear that lowering
LDL-C to levels lower than previously recommended
had beneﬁt in the IMPROVE-IT trial, with regard to the
primary endpoint and with regard to most of the spe-
ciﬁc components of the primary endpoint.
It remains unclear how low we should take LDL-C
levels for optimum beneﬁt in the post-ACS patientpopulation. Previous guidelines and recommenda-
tions have suggested an LDL-C threshold of 70 mg/dl
while the most recent ACC/AHA lipid guidelines sug-
gested using a high dose of a high-intensity statin to
achieve a 40% to 50% LDL-C reduction. Data from the
PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evalu-
ation and Infection Therapy–Thrombolysis In
Myocardial Infarction 22) trial presented by Ridker
et al. (11) suggested maximal risk reduction occurred
when the on-treatment LDL-Cwas at or below 70mg/dl
and that results of the high-sensitivity C-reactive
protein (hs-CRP) test showed the concentration was at
or below 2 mg/dl. Observations by Ridker et al. (11)
(supported by Morrow et al. [12] from the A to Z trial).
The recent work from the IMPROVE-IT trial extended
those observations by suggesting additional risk
reduction in post-ACS patients occurs when an on
treatment LDL-C level near 50 mg/dl is achieved (13).
Will this goal be attainable in most post-ACS patients?
Likely not, when statin monotherapy is used in pa-
tients who are post-ACS (13). The IMPROVE-IT trial
demonstrates that additional LDL-C lowering using
combination therapy (statin and ezetimibe) can ach-
ieve what statin monotherapy likely cannot achieve
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364consistently. The physician will need to escalate post-
ACS lipid-altering therapy to combination therapy
with statin and ezetimibe if the choice is to lower the
LDL-C to below 70 mg/dl (11). A regression curve
comparing clinical efﬁcacy plotted against on
treatment LDL-C predicted the beneﬁt that the
IMPROVE-IT trial demonstrated (Figure 1). It remains
unclear how low LDL-C must be taken in the post-ACS
population to achieve maximal risk reduction. The
IMPROVE-IT trial extended our knowledge by sug-
gesting a beneﬁt at or around 50 mg/dl, yet it may not
be the ﬁnal word to answer this question. There are at
least 3 ongoing outcome trials evaluating even lower
LDL-C goals utilizing combination therapy of a statin
with a PCSK-9 antibody.
The work by Murphy et al. (7) extends our knowl-
edge about lipid-modifying therapy by demonstrating
a beneﬁt across both initial and subsequent events
which composed the primary endpoint of the trial. It is
not within our expertise to discuss the statistical
justiﬁcation of such analyses, but they are well
defended by the authors and by previous work. It is
reassuring to see that other atheroinﬂammatory-
thrombotic endpoint events are favorably reduced by
aggressive LDL-C lowering in the post-ACS population.
WHAT IS YET UNANSWERED ABOUT
LIPID-MODIFYING THERAPY POST-ACS?
Data from IMPROVE-IT failed to demonstrate a sta-
tistically signiﬁcant reduction in cardiovascular
mortality despite a large sample size and multi-year
patient follow-up. It is unclear why reducing the
risk of nonfatal myocardial infarction and ischemicstroke did not translate into an overall reduction
in cardiovascular mortality. This divergence of
cardiovascular events from overall mortality and
cardiovascular mortality has been also seen in other
cardiovascular lipid-lowering trials. It is also unclear
why the authors did not report total mortality data in
addition to cardiovascular mortality as total mortality
is generally considered a reliable hard endpoint These
data are important in establishing the overall safety
of combination lipid-modifying pharmacotherapy in
post-ACS patients.
We also speculate that data from IMPROVE-IT are
the ﬁrst in what is expected to be a number of publi-
cations which will challenge the premise of the 2013
ACC/AHA lipid guidelines, namely, that achieved
speciﬁc LDL-C goals are not as essential as what dose of
statin the patient takes. We suggest that the data from
IMPROVE-IT, like the prior data from PROVE-IT,
strongly suggest that LDL-C values are crucial, espe-
cially in the post-ACS population and that lower LDL-C
is better at reducing future cardiovascular events. Will
an LDL-C on lipid-lowering treatment of 50 mg/dl or
less serve to lessen the risk posed by this modern
“sword of Damocles”? Only time will tell, but the work
by Murphy et al. (7) and the larger IMPROVE-IT trial
data certainly challenge us to critically rethink howwe
approach lipid treatment in the post-ACS population.
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